GSK plc (NYSE:GSK) Shares Bought by Roberts Wealth Advisors LLC

Roberts Wealth Advisors LLC boosted its position in shares of GSK plc (NYSE:GSKFree Report) by 9.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 67,992 shares of the pharmaceutical company’s stock after acquiring an additional 5,699 shares during the period. Roberts Wealth Advisors LLC’s holdings in GSK were worth $2,423,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Arete Wealth Advisors LLC acquired a new position in GSK in the first quarter valued at $357,839,000,000. SeaCrest Wealth Management LLC increased its holdings in shares of GSK by 4.9% in the first quarter. SeaCrest Wealth Management LLC now owns 27,221 shares of the pharmaceutical company’s stock valued at $969,000 after purchasing an additional 1,273 shares during the period. Ariel Investments LLC lifted its stake in shares of GSK by 9.3% in the 4th quarter. Ariel Investments LLC now owns 185,288 shares of the pharmaceutical company’s stock worth $6,511,000 after acquiring an additional 15,727 shares during the period. B. Riley Wealth Advisors Inc. lifted its stake in shares of GSK by 15.9% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 40,781 shares of the pharmaceutical company’s stock valued at $1,445,000 after purchasing an additional 5,606 shares during the period. Finally, Caldwell Sutter Capital Inc. purchased a new stake in GSK during the first quarter worth about $129,000. 13.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on GSK. HSBC assumed coverage on GSK in a research report on Friday, July 14th. They issued a “reduce” rating for the company. downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 2nd. Four equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $1,533.00.

Check Out Our Latest Stock Report on GSK

GSK Stock Up 0.2 %

Shares of GSK traded up $0.07 during trading on Tuesday, reaching $37.42. The company’s stock had a trading volume of 512,705 shares, compared to its average volume of 3,333,666. GSK plc has a twelve month low of $28.47 and a twelve month high of $39.74. The company has a quick ratio of 0.63, a current ratio of 0.88 and a debt-to-equity ratio of 1.28. The company has a market cap of $76.62 billion, a price-to-earnings ratio of 4.26, a P/E/G ratio of 1.98 and a beta of 0.68. The company has a fifty day moving average of $35.21 and a two-hundred day moving average of $35.37.

GSK (NYSE:GSKGet Free Report) last issued its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.12. The firm had revenue of $8.98 billion for the quarter, compared to the consensus estimate of $8.49 billion. GSK had a net margin of 50.26% and a return on equity of 55.93%. On average, sell-side analysts predict that GSK plc will post 3.77 EPS for the current fiscal year.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 18th will be given a dividend of $0.3613 per share. The ex-dividend date of this dividend is Thursday, August 17th. This represents a $1.45 dividend on an annualized basis and a yield of 3.86%. GSK’s dividend payout ratio (DPR) is presently 16.10%.

About GSK

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Stories

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with's FREE daily email newsletter.